116 related articles for article (PubMed ID: 25702665)
1. Nonrandomized comparison between concomitant and sequential chemoradiotherapy with anthracyclines in breast cancer.
Leonardi MC; Morra A; Santoro L; Balduzzi A; Ivaldi GB; Vischioni B; Ferrari A; Fodor C; Dell'Acqua V; Cardinale DM; Cipolla C; Luini A; Colleoni M; Jereczek-Fossa BA; Orecchia R
Tumori; 2015; 101(1):64-71. PubMed ID: 25702665
[TBL] [Abstract][Full Text] [Related]
2. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
3. [Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].
Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Miny-Buffet J; Favre A; Azria D; Body G; Le Floch O; Calais G
Cancer Radiother; 2006 Jun; 10(4):158-67. PubMed ID: 16632399
[TBL] [Abstract][Full Text] [Related]
4. Concomitant adjuvant chemo-radiation therapy with anthracycline-based regimens in breast cancer: a single centre experience.
Livi L; Meattini I; Scotti V; Saieva C; Simontacchi G; Marrazzo L; Franzese C; Cassani S; Paiar F; Di Cataldo V; Nori J; Jose Sanchez L; Bianchi S; Cataliotti L; Biti G
Radiol Med; 2011 Oct; 116(7):1050-8. PubMed ID: 21424317
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
7. A feasibility study of neo-adjuvant low-dose fractionated radiotherapy with two different concurrent anthracycline-docetaxel schedules in stage IIA/B-IIIA breast cancer.
Nardone L; Valentini V; Marino L; De Santis MC; Terribile D; Franceschini G; Balducci M; Mantini G; Mattiucci G; Mulè A; Belli P; Masetti R
Tumori; 2012; 98(1):79-85. PubMed ID: 22495705
[TBL] [Abstract][Full Text] [Related]
8. Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study.
Nardone L; Diletto B; De Santis MC; D' Agostino GR; Belli P; Bufi E; Franceschini G; Mulé A; Sapino A; Terribile D; Valentini V
Breast; 2014 Oct; 23(5):597-602. PubMed ID: 24998453
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Breteau N; Body G; Azria D; Le Floch O; Calais G
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):324-32. PubMed ID: 16542788
[TBL] [Abstract][Full Text] [Related]
10. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
De Santis MC; Bonfantini F; Di Salvo F; Fiorentino A; Riboldi VM; Di Cosimo S; Bianchi GV; Gennaro M; Cosentino V; Sant M; Pignoli E; Valdagni R; Lozza L
Clin Breast Cancer; 2018 Jun; 18(3):e363-e371. PubMed ID: 28958838
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
De Santis MC; Bonfantini F; Di Salvo F; Dispinzieri M; Mantero E; Soncini F; Baili P; Sant M; Bianchi G; Maggi C; Di Cosimo S; Agresti R; Pignoli E; Valdagni R; Lozza L
Breast; 2016 Oct; 29():90-5. PubMed ID: 27476083
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
14. [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].
Kirova YM; Caussa L; Granger B; Savignoni A; Dendale R; Campana F; Tournat H; Pierga JY; Fourquet A; Bollet MA
Cancer Radiother; 2009 Jul; 13(4):276-80. PubMed ID: 19447661
[TBL] [Abstract][Full Text] [Related]
15. Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up.
Wu SP; Tam M; Vega RM; Perez CA; Gerber NK
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):541-548. PubMed ID: 29280448
[TBL] [Abstract][Full Text] [Related]
16. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
[TBL] [Abstract][Full Text] [Related]
18. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
19. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
